University of Michigan Rogel Cancer Center: Leukemia trials
The registry lists 10 Leukemia studies with University of Michigan Rogel Cancer Center as lead sponsor. 0 are open to participants now and 4 have results posted.
Phase 1 3Phase 2 7No phase 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid LeukemiaCompletedNCT02328755Phase 1/2Results posted
- Multi-center Study of Myeloablative Allo Stem Cell Transplant for Non-remission AML Using CloBu4 RegimenCompletedNCT01457885Phase 2Results posted
- Blood Stem Cell Transplantation for the Treatment of Older Patients With Acute Myelogenous LeukemiaCompletedNCT00623935Phase 2Results posted
- Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid LeukemiaTerminatedNCT00573378Phase 2Results posted
- Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaWithdrawnNCT04845035Phase 2
- Pharmacists Coordinated Care Oncology Model (PCOM) for Patients Taking Oral Anti-cancer MedicationsTerminatedNCT04595851Not applicable
- The SMART CART Study: Health Information TechnologyCompletedNCT04051216Not applicable
- Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)WithdrawnNCT02677948Phase 1/2
- RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.WithdrawnNCT01188889Phase 1/2
- Discontinuation of Imatinib Mesylate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With Interferon-AlphaTerminatedNCT01073436